Leukemia Clinical Trials

A listing of Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 537 clinical trials
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia

with mitoxantrone liposome in the treatment of relapsed or refractory acute myeloid leukemia (AML), and determine the recommended dose for phase II (RP2D); Phase II is a multi-center, exploratory study

  • 0 views
  • 07 Oct, 2022
  • 1 location
LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

This is a single-center, single-arm, open-label phase I clinical study to determine the safety and efficacy of LILRB4 STAR-T cells in relapsed/refractory acute myeloid leukemia subjects.

  • 0 views
  • 07 Oct, 2022
  • 1 location
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

Background Most people with hairy cell leukemia have a BRAF gene mutation. They can be treated with BRAF inhibitors, drugs that target this mutation. For people

  • 6 views
  • 04 Oct, 2022
  • 1 location
  • 222 views
  • 07 Oct, 2022
  • 22 locations
A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)

This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy and PK of APG-2575 in combination with Azacitidine in the patients with AML/MPAL or MDS/CMML. The study consists of dose escalation (Part I) and dose expansion phase (Part II)

  • 0 views
  • 04 Oct, 2022
  • 3 locations
Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (VEN-OM)

This will be a single arm, open label Phase Ib dose-escalation study of the combination of VEN and OM, conducted using an innovative Bayesian Optimal Interval-design, to find the MTD in participants with relapsed/refractory hematologic malignancies including those failing treatment with venetoclax-containing regimens. Treatment plan will consist of an induction …

  • 0 views
  • 07 Oct, 2022
  • 1 location
A Phase 1b Study of JNJ-75276617 in Combination With AML Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of JNJ-75276617 in combination with AML directed therapies (dose selection) and further to evaluate safety and tolerability of JNJ-75276617 in combination with AML directed therapies at the RP2D(s) (dose expansion).

venetoclax
azacitidine
  • 0 views
  • 14 Sep, 2022
  • 3 locations
An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission

The purpose of this study is to evaluate the efficacy and safety of CC-486 in Chinese participants with acute myeloid leukemia in complete remission.

azacitidine
consolidation therapy
chronic myelomonocytic leukemia
remission
  • 0 views
  • 07 Oct, 2022
  • 6 locations
  • 0 views
  • 07 Oct, 2022
  • 9 locations
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML

This is a Phase 1/2a, multicenter, open-label, first-in-human (FIH) study of VOR33 in participants with AML who are undergoing human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (HCT).

direct bilirubin
hla-a
blast cells
remission
ejection fraction
  • 0 views
  • 07 Oct, 2022
  • 7 locations